Phase I clinical trial - Phases précoces tumeurs solides

BI 1336.1
Phases précoces tumeurs solides
Essai clinique fermé
Public cible
A First-in Human Phase I, non-randomized, open-label, multicenter dose escalation trial of BI 836880 administered by repeated intravenous infusions in patients with solid tumors.
Description de l'essai

This is a phase 1 trial évaluating an bispecific antiangiogenic antibody targeting VEGF and angiopoitin 2 in patients with any kind of cancer. The drug is administered IV every 3 weeks.